Maria Mar Hernandez Guillamon Senior Researcher, Neurovascular Research Lab, VHIR. Instituciones de las que forman parte Investigador/a principal Enfermedades Neurovasculares Vall Hebron Institut de Recerca Twitter Email Maria Mar Hernandez Guillamon Twitter Email Instituciones de las que forman parte Investigador/a principal Enfermedades Neurovasculares Vall Hebron Institut de Recerca Senior Researcher, Neurovascular Research Lab, VHIR.
Dr. Mar Hernández-Guillamon has dedicated her career to the study of cerebral amyloid angiopathy (CAA) and other pathologies associated with the deposition of amyloid-beta (Abeta). In 2013, she was awarded by Carlos III Spanish Health Institute with the Miguel Servet contract to establish the Cerebral Amyloidosis line of research at VHIR. Her group has positioned in forefront of the Abeta-pathologies field, studying the molecular mechanisms involved in the Abeta transport and metabolism using in vitro and in vivo models. Her lab has also dedicated to the clinical research and discovery of biomarkers associated with CAA and other cerebrovascular diseases. The translational research developed by Dr. Hernandez-Guillamon's group has allowed the achievement of important aims to date, as demonstrated by the scientific production obtained (h-index= 35, 80 publications, >3700 citations) and the continuous leadership of national and international projects.
Proyectos IBCAA Snowball - Image guided non-invasive brain stimulation for safe and therapeutically effective modulation of blood-brain-barrier function and neural networks in cerebral amyloid angiopathy IP: Maria Mar Hernandez Guillamon Colaboradores: - Entidad financiadora: Instituto de Salud Carlos III Financiación: Referencia: EC/ERANET_JNPD/2020/HERNANDEZ Duración: - Implicaction of proteins associated with vascular beta-amyloid in Cerebral Amyloid Angiopathy IP: Maria Mar Hernandez Guillamon Colaboradores: Jessica Camacho Soriano, Olga Maisterra Santos, Olalla Pancorbo Rosal Entidad financiadora: Instituto de Salud Carlos III Financiación: 169400 Referencia: PI20/00465 Duración: 01/01/2021 - 30/06/2025 Nanotechnology albumin-based approach for the diagnosis and future treatment of Alzheimer's Disease IP: Maria Mar Hernandez Guillamon Colaboradores: - Entidad financiadora: Grifols S.A. Financiación: 50000 Referencia: GRIFOLS/AAAP/2019-20/HERNANDEZ Duración: 01/12/2020 - 30/11/2021 Discovery of novel biomarkers related to vascular dysfunction in cerebral â-amyloidosis IP: Maria Mar Hernandez Guillamon Colaboradores: Laia Perez Lasarte Entidad financiadora: Fundació Institut de Recerca HUVH Financiación: 46800 Referencia: VHIR/PREDOC/2017/MARAZUELA Duración: 01/07/2018 - 30/06/2021 Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3 Página 4 Página 5 … Siguiente página › Última página »
